AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On the bad news side, the company’s selumetinib failed another clinical trial.
July 26, 2018
· 2 min read
·